39 results about "Phosphoprotein" patented technology

The application provides a kind of double ligand HOF functionalized magnetic nanomaterial and its preparation method and application, belongs to functionalized magnetic material preparation technical field.The method first synthesizes Fe3O4NPs, NH3·H2O is added to solution to be alkaline, then the temperature is heated to react, obtains Fe3O4NPs suspension liquid;Fe3O4NPs suspension liquid is added to oleic acid stirring, and the obtained Fe3O4@OA;Guanidine hydrochloride monomer is dissolved in solvent, then Fe3O4@OA is dispersed in stirring, and Fe3O4@GD is obtained;Finally, Fe3O4@GD is mixed with GD, boric acid, triethylamine and 1,2,4-trichlorobenzene containing solution stirring, and double ligand HOF functionalized magnetic nanomaterial is obtained.The functional material of the application can also effectively capture glycoprotein, and identify glycoprotein and phosphoprotein.

An antisense oligonucleotide (ASO) that is capable of binding to a target sequence in a mRNA of a secreted phosphoprotein 1 (SPP1) or osteopontin (OPN) gene, the mRNA having a start codon in an open reading frame encoding the SPP1 or OPN, and the target sequence including the start codon in the open reading frame of the mRNA. Binding of the ASO to the target sequence disrupts translation of the ORF encoding the SPP1 or OPN. Alternatively, an ASO wherein the ASO is capable of binding to a target sequence in a pre-mRNA of a SPP1 or OPN gene. Also double-stranded DNA or RNA molecules capable of binding to a target sequence in a mRNA or pre-mRNA of a SPP1 or OPN gene. Additionally, pharmaceutical compositions and methods of treatments using the ASOs or double-stranded DNA or RNA molecules.

The present invention provides a temperature-sensitive negative-strand RNA virus or virus vector and an RNA genome thereof. According to the invention, provided is a negative-strand RNA virus or virus vector having a negative-strand RNA genome wherein the phosphoprotein (P protein) on the RNA genome has an amino acid mutation(s) corresponding to a substitution(s) in an amino acid(s) of the P protein corresponding to one or more or all of D433, R434, and K437 and optionally further has an amino acid mutation corresponding to a further amino acid substitution in an amino acid of the P protein corresponding to L511.

Provided are oligomeric compounds, methods, and pharmaceutical compositions for reducing the amount or activity of PLN RNA in a cell or animal, and in certain instances reducing the amount of phospholamban protein in a cell or animal. Such oligomeric compounds, methods, and pharmaceutical compositions are useful to treat cardiomyopathy, heart failure, or arrhythmia.

The invention provides application of phosvitin and phosphopeptides thereof in preparation of in-vitro anticoagulant drugs, specifically, blood coagulation is caused by a series of enzymatic reactions, the chemical nature of the blood coagulation is that fibrinogen in a sol state is converted into fibrin in a gel state, and the main substance for catalyzing the reactions is thrombin. The phosvitin can inhibit the activity of thrombin in blood so as to prolong the blood coagulation time to achieve the anticoagulation effect. The application proves that phosvitin has the potential of being developed into an in-vitro anticoagulant.

This invention relates to the field of biomedical technology, specifically to a composite adsorption material for enriching phosphopeptides of egg yolk high-phosphoproteins and its preparation method. The material comprises, from the inside out: Zr 4+ and La 3+ A bimetallic-doped TiO2 matrix, an EDTA passivation layer, and an amino-functionalized layer were co-doped. The preparation process included: synthesizing the bimetallic-doped TiO2 matrix via a sol-gel method, passivating and coating it with EDTA solution after two-step calcination, and then grafting the amino layer using APTES / acetic acid catalysis. This material exhibits both high specific surface area and specific binding capacity, achieving an adsorption capacity of 67.5 mg / g. After 10 cycles, the capacity retention rate is >92.8%, enabling efficient enrichment of high-purity PPPs, making it suitable for the industrial production of functional foods and pharmaceuticals.

A method for detection or monitoring status of traumatic brain injury (TBI) and / or spinal cord injury (SCI) in a subject is provided. In one embodiment, the method comprises contacting a specimen of bodily fluid obtained from the subject with reagents for assaying for a marker of TBI selected from aldolase C (ALDOC) and brain lipid binding protein (BLBP / FABP7), or a trauma-specific break down product (BDP) of ALDOC or BLBP / FABP7. The method further comprises measuring the amount of marker present in the specimen as compared to a control sample, and determining the presence of TBI or SCI when an elevated amount of marker is present in the specimen compared to the control sample. Optionally, the method further comprises measuring the amount of glutamine synthetase (GS), astrocytic phosphoprotein PEA-15 (PEA15), αB-crystallin (CRYAB / HSP27), a trauma-specific proteolytic cleavage product of ALDOC, GS, PEA15, or CRYAB, or any combination of two or more thereof.

The present invention relates to improved complexes of amorphous calcium phosphate and / or amorphous calcium fluoride phosphate stabilised by phosphopeptides / phosphoproteins by addition of stannous ions. These complexes have anticariogenic properties useful to protect tooth structures as they remineralize (repair) early stages of dental caries and have other dental / medical applications (including anti-calculus, anti-erosion / corrosion and anti-dentinal hypersensitivity). Methods of making the complexes of the invention and of treatment or prevention of various dental conditions including dental caries, dental calculus, dental erosion / corrosion and dental hypersensitivity are also provided.

The present invention relates to a method for rescue of Vesicular Stomatitis Virus (VSV) from DNA in a HEK293 cell line or a HEK293 cell line adapted to suspension growth comprising (a) providing cells from a HEK293 cell line or a HEK293 cell line adapted to suspension growth in cell culture, (b) transfecting the cells with at least one plasmid, wherein the at least one plasmid comprises (i) an expression cassette comprising a VSV genomic cDNA; (ii) at least one expression cassette encoding VSV nucleoprotein (N) protein, VSV phosphoprotein (P) protein, and VSV large (L) protein; and (iii) an expression cassette encoding SV40 Large T antigen; (c) culturing the transfected cells; and (d) harvesting the cell culture supernatant comprising the rescued VSV. Also provided is the use of a HEK293 cell line or a HEK293 cell line adapted to suspension growth for rescue of Vesicular Stomatitis Virus (VSV) or the use of a plasmid encoding SV40 Large T antigen for rescue of Vesicular Stomatitis Virus (VSV) in a HEK293 cell line or a HEK293 cell line adapted to suspension growth HEK293-F cells by means of transient transfection.

Provided herein are methods of treating acute leukemia, e.g., acute myeloid leukemia (AML), in an individual, e.g., an individual having a mutation in the nucleophosmin 1 (NPM1) gene or a rearrangement in the lysine [K]-methyltransferase 2A (KMT2A) gene, the methods comprising administering the menin inhibitor diftomenib to the individual at a dose of 600 milligrams daily.

To reduce the amount or activity of PLN RNA in cells or animals, in certain cases, oligomeric compounds, methods, and pharmaceutical compositions are provided for reducing the amount of phospholamban protein in cells or animals. Such oligomeric compounds, methods, and pharmaceutical compositions are useful for treating cardiomyopathy, heart failure, or arrhythmias.

Oligomeric compounds, methods, and pharmaceutical compositions for reducing the amount or activity of PLN RNA and, in some cases, the amount of phosphoreceptor protein in a cell or animal are provided. Such oligomeric compounds, methods, and pharmaceutical compositions are useful for the treatment of cardiomyopathy, heart failure, or arrhythmia.

The present invention provides peptides that specifically bind to maternal autoantibodies that are generated in the mother or potential mother against one or more endogenous polypeptide antigens selected from lactate dehydrogenase A (LDH A), lactate dehydrogenase B (LDH B), stress-induced phosphoprotein 1 (STIP1), guanine deaminase (GDA), Y Box Binding Protein 1 (YBX1), collapsin response mediator protein 1 (CRMP1), and collapsin response mediator protein 2 (CRMP2). The peptides described herein are useful for determining a risk of an offspring for developing an autism spectrum disorder (ASD) by detecting the presence of maternal autoantibodies in a biological sample of the mother or potential mother. The peptides or mimotopes thereof can also be administered to the mother or potential mother to block the binding between maternal autoantibodies and their antigens, thereby neutralizing the maternal autoantibodies.

The present invention relates to a polypeptide composition, comprising a nucleic acid encoding a mutant pp65 polypeptide, the nucleic acid being mRNA, viral RNA, or replicon RNA. The composition is capable of expressing the mutant pp65 polypeptide in vivo, eliciting a specific humoral or cellular immune response against the pp65 polypeptide, and producing an effector cell having a tumor cell killing effect and a specific antibody.

The invention provides a pulp capping material comprising bioactive glass fibers, mesoporous tricalcium silicate, and zirconia dioxide. The initial setting time of this pulp capping material can be reduced to 7 minutes. The material exhibits no significant cytotoxicity and can significantly enhance cell viability. Additionally, it increases the expression of alkaline phosphatase and Dentin Sialophosphoprotein mineralization genes in dental pulp stem cells.

To provide novel nucleic acid sequences, vectors, modified cells, peptides, and pharmaceutical compositions which are useful in the treatment of human subjects, having a mutant nucleophosmin (ΔNPM1 or NPM1 mut) positive haematological malignancy.SOLUTION: The present invention provides an isolated nucleic acid sequence encoding (a) a polypeptide comprising a CDR3 of a TCR α chain polypeptide that specifically binds to a peptide selected from a specific group of sequences and / or (b) a polypeptide comprising a CDR3 of a TCR β chain polypeptide that specifically binds to a peptide selected from a specific group of sequences.SELECTED DRAWING: Figure 1

The present invention discloses a preparation method and application of a bionic multi-stage spherical mineralized collagen scaffold. The collagen mineralization area of ​​the prepared mineralized collagen scaffold presents a specific distribution, and a bionic multi-stage spherical structure appears, which can highly simulate the mineralization pattern of the mineralization front of the organism. The mineralized collagen scaffold is formed by inducing the mineralization of type I collagen within collagen fibers by a specific mineralization system prepared in vitro, and presents a spherical structural unit after multi-stage assembly. The above-mentioned specific mineralization system is a calcium-phosphate precursor system stabilized by egg yolk phosphoprotein. The bionic multi-stage spherical mineralized collagen scaffold material of the present invention has excellent bone induction properties and unique mechanical properties, and is non-cytotoxic, and can be used as a bone tissue engineering scaffold material to promote bone defect repair.

The present disclosure provides gRNAs targeting the phospholamban (PLN) gene, expression cassettes, vectors, virions and compositions comprising the same, as well as methods useful for the treatment or prevention of heart disease. In some embodiments, the present disclosure provides expression cassettes and vectors comprising a polynucleotide encoding a Cas endonuclease protein operably linked to a protein expression-driving promoter (e.g., a human troponin T promoter) and / or a polynucleotide encoding a gRNA targeting a sequence of the PLN gene comprising a mutation or deletion operably linked to an RNA expression-driving promoter. The present disclosure also provides guide RNAs, expression cassettes, vectors, virions and compositions for specifically targeting PLN gene comprising a deletion of Arg14.

The invention discloses a specific monoclonal antibody for vasodilatation-stimulating phosphoprotein and application of the specific monoclonal antibody. In the monoclonal antibody, the amino acid sequence of a heavy chain variable region is as shown in SEQ ID NO.1, and the amino acid sequence of a light chain variable region is as shown in SEQ ID NO.5. The monoclonal antibody only recognizes VASP and does not have cross reaction with EVL and Mena of the same family, and the antibody can recognize all isomers of the VASP and can recognize phosphorylated and non-phosphorylated VASP.

The present invention relates to a gene construct comprising a nucleotide encoding a decoy peptide that inhibits dephosphorylation of a protein phosphatase 1 (PP1)-mediated phosphoprotein (PLB) and a nucleotide encoding a CCN5 protein or a fragment thereof; the invention also relates to a pharmaceutical composition for preventing and treating heart diseases. The pharmaceutical composition comprises the gene construct. The pharmaceutical composition for preventing and treating heart diseases according to the present invention simultaneously expresses a decoy peptide that inhibits PP1-mediated dephosphorylation and a CCN5 protein, thereby exhibiting a synergistic therapeutic effect, and thus can be effectively used for preventing or treating heart diseases.

This invention discloses egg-derived calcium absorption-promoting peptides, their preparation methods, and applications, belonging to the field of peptide technology. The egg-derived calcium absorption-promoting peptides include egg yolk high-phosphorus protein-derived peptides or shell membrane-derived peptides; the amino acid sequence of the egg yolk high-phosphorus protein-derived peptide is LSKIWGR, and the amino acid sequence of the shell membrane-derived peptide is GPAGFPGAP. This invention is the first to screen and identify two egg-derived peptides, LSKIWGR and GPAGFPGAP, and evaluates their calcium absorption-promoting function using physicochemical activity combined with cell models. It was found that these two peptides not only bind efficiently to calcium ions but also have a certain ability to enhance the transmembrane transport activity of calcium, thus promoting calcium ion absorption. Both egg-derived peptides provided by this invention have the potential to be developed into calcium supplements and / or calcium absorption-promoting products.

The invention discloses an N-acetylglucosamine transferase mutant and application thereof in production of L-tryptophan, and belongs to the technical field of genetic engineering. In order to solve the problems of yield limitation and the like caused by excessive consumption of phosphoenolpyruvic acid in the production of L-tryptophan, the invention weakens a phosphoprotein coding gene crr on escherichia coli; meanwhile, a uridine diphosphate galactose pyranose mutase gene glf and a glucokinase gene glk of the pseudomonas mobilis and an endogenous galactose H (+) transporter enzyme gene galP of escherichia coli are integrated at a pflB site, and a genetically engineered bacterium is obtained; mutagenesis is carried out on the basis to obtain a mutant strain with improved L-tryptophan yield; and the N-acetylglucosamine transferase mutants nagC and nagE are obtained by virtue of sequencing. Fermentation proves that overexpression of the mutant nagC or nagE or simultaneous overexpression of the mutants nagC and nagE in the genetically engineered bacteria can improve the yield of L-tryptophan.

The invention discloses selenium-containing bioglass, preparation thereof and application of the selenium-containing bioglass in a pulp covering material for repairing dental pulp injury, or application of the selenium-containing bioglass in expression promoters of RUNX transcription factor 2, dentin saliva phosphoprotein and dentin matrix acid phosphoprotein 1. The preparation method comprises the following steps: preparing Se-Ca-Si-P quaternary system sol by adopting a sol-gel method, sealing and aging at room temperature until the sol is gel-shaped, and drying; and grinding the dried product, calcining, carrying out secondary grinding on the calcined powder, and screening to obtain the selenium-containing bioglass. The material not only can rapidly induce bone-like apatite deposition, has excellent antioxidant and antibacterial activity, but also can remarkably promote proliferation and migration of dental pulp stem cells, effectively up-regulate expression of a dental differentiation gene RUNX transcription factor 2, dentin saliva phosphoprotein and dentin matrix acid phosphoprotein 1, and can promote the growth of dental pulp stem cells. The material can be used as a pulp capping material in the aspects of dental pulp injury repair, dentin regeneration and the like.

The present invention relates to a polypeptide composition comprising a nucleic acid encoding a mutated pp65 polypeptide, the nucleic acid being mRNA, viral RNA or replicon RNA, said composition being capable of expressing the mutated pp65 polypeptide in vivo, eliciting a specific humoral or cellular immune response against the pp65 polypeptide, producing effector cells and specific antibodies having a tumor cell killing effect.

The present invention relates to improved complexes of amorphous calcium phosphate and / or amorphous calcium fluoride phosphate stabilised by phosphopeptides / phosphoproteins by addition of stannous ions. These complexes have anticariogenic properties useful to protect tooth structures as they remineralize (repair) early stages of dental caries and have other dental / medical applications (including anti-calculus, anti-erosion / corrosion and anti-dentinal hypersensitivity). Methods of making the complexes of the invention and of treatment or prevention of various dental conditions including dental caries, dental calculus, dental erosion / corrosion and dental hypersensitivity are also provided.

The application discloses a vascular expansion stimulating phosphoprotein specific monoclonal antibody and application. In the monoclonal antibody, the amino acid sequence of the heavy chain variable region is shown as SEQ ID NO. 1, and the amino acid sequence of the light chain variable region is shown as SEQ ID NO. 5. The monoclonal antibody only recognizes VASP, and does not exist cross reaction with EVL and Mena in the same family, and the antibody can recognize all isomers of VASP, and can recognize phosphorylated and non-phosphorylated VASP.

Provided are oligomeric compounds, methods, and pharmaceutical compositions for reducing the amount or activity of PLN RNA in a cell or animal, and in certain instances reducing the amount of phospholamban protein in a cell or animal. Such oligomeric compounds, methods, and pharmaceutical compositions are useful to treat cardiomyopathy, heart failure, or arrhythmia.

The present disclosure provides gRNAs targeting the phospholamban (PLN) gene, expression cassettes, vectors, virions and compositions comprising the same, as well as methods useful for the treatment or prevention of heart disease. In some embodiments, the present disclosure provides expression cassettes and vectors comprising a polynucleotide encoding a Cas endonuclease protein operably linked to a protein expression-driving promoter (e.g., a human troponin T promoter) and / or a polynucleotide encoding a gRNA targeting a sequence of the PLN gene comprising a mutation or deletion operably linked to an RNA expression-driving promoter. The present disclosure also provides guide RNAs, expression cassettes, vectors, virions and compositions for specifically targeting PLN gene comprising a deletion of Arg14.

The present invention provides methods and compositions comprising a C-terminal fragment of the Astrocytic phosphoprotein (PEA-15) protein in the treatment and / or prevention of a disorder or a disease Preferably, the disorder or a disease is a neurodevelopmental, a neurological or a psychiatric disorder or disease.

The application belongs to the technical field of biology and relates to a biomarker for early diagnosis of non-small cell lung cancer and application thereof. The biomarker comprises a combination of secreted phosphoprotein 1, epithelial cell adhesion molecule and matrix metallopeptidase 14, and / or a combination of a coding nucleic acid of secreted phosphoprotein 1, a coding nucleic acid of epithelial cell adhesion molecule and a coding nucleic acid of matrix metallopeptidase 14; the coding nucleic acid comprises mRNA or cDNA. A non-small cell lung cancer circulating tumor cell score diagnosis model constructed by taking the biomarker as a feature has a diagnosis accuracy of 87.5% in a test set, and the sensitivity and specificity are 92.5% and 82.5% respectively. Compared with existing tumor indexes in the clinic, the biomarker can detect cancer at an earlier stage and is conducive to early screening of non-small cell lung cancer.